bioAffinity Technologies, Inc.
- BIAF
- NASDAQ
- Medical - Diagnostics & Research
- Cancer Diagnostics
- Precision Therapeutics
- Lung Cancer Detection
$3.58
Today +2.12%Quote Oct 20, 2026, 02:09 PM UTC
−62.78%over the last month
Max drawdown −62.8%From 1-month high −62.8%3 months −66.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About bioAffinity Technologies
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ
Employees
57
Market value
$29.0M
Quote Oct 20
Floor
$3.23
9.9% below price
Resistance
$3.90
8.9% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BIAFPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free